Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Eliezer Mendel Van Allen, M.D.

Co-Author

This page shows the publications co-authored by Eliezer Van Allen and David Liu.
Connection Strength

3.530
  1. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat Commun. 2017 12 19; 8(1):2193.
    View in: PubMed
    Score: 0.760
  2. Toward Molecularly Driven Precision Medicine in Lung Adenocarcinoma. Cancer Discov. 2017 06; 7(6):555-557.
    View in: PubMed
    Score: 0.731
  3. Integrated molecular drivers coordinate biological and clinical states in melanoma. Nat Genet. 2020 12; 52(12):1373-1383.
    View in: PubMed
    Score: 0.233
  4. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat Med. 2019 12; 25(12):1916-1927.
    View in: PubMed
    Score: 0.217
  5. Integrative Molecular Characterization of Resistance to Neoadjuvant Chemoradiation in Rectal Cancer. Clin Cancer Res. 2019 09 15; 25(18):5561-5571.
    View in: PubMed
    Score: 0.211
  6. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018 09; 50(9):1271-1281.
    View in: PubMed
    Score: 0.199
  7. The long tail of oncogenic drivers in prostate cancer. Nat Genet. 2018 05; 50(5):645-651.
    View in: PubMed
    Score: 0.194
  8. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncol. 2016 Aug 01; 2(8):1094-6.
    View in: PubMed
    Score: 0.173
  9. The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79.
    View in: PubMed
    Score: 0.172
  10. Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. Clin Cancer Res. 2021 Apr 01; 27(7):2011-2022.
    View in: PubMed
    Score: 0.058
  11. Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy. J Clin Invest. 2020 08 03; 130(8):4266-4281.
    View in: PubMed
    Score: 0.057
  12. Inactivation of Fbxw7 Impairs dsRNA Sensing and Confers Resistance to PD-1 Blockade. Cancer Discov. 2020 09; 10(9):1296-1311.
    View in: PubMed
    Score: 0.056
  13. ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer. Cancer Res. 2020 06 01; 80(11):2094-2100.
    View in: PubMed
    Score: 0.055
  14. Identification of cancer driver genes based on nucleotide context. Nat Genet. 2020 02; 52(2):208-218.
    View in: PubMed
    Score: 0.055
  15. CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer. Cell Rep. 2019 11 19; 29(8):2355-2370.e6.
    View in: PubMed
    Score: 0.054
  16. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3.
    View in: PubMed
    Score: 0.054
  17. Intrinsic Resistance to Immune Checkpoint Blockade in a Mismatch Repair-Deficient Colorectal Cancer. Cancer Immunol Res. 2019 08; 7(8):1230-1236.
    View in: PubMed
    Score: 0.053
  18. A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade. Cell. 2018 11 01; 175(4):984-997.e24.
    View in: PubMed
    Score: 0.050
  19. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer. J Clin Invest. 2018 10 01; 128(10):4441-4453.
    View in: PubMed
    Score: 0.050
  20. ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. Clin Cancer Res. 2019 02 01; 25(3):977-988.
    View in: PubMed
    Score: 0.049
  21. Convergent Therapeutic Strategies to Overcome the Heterogeneity of Acquired Resistance in BRAFV600E Colorectal Cancer. Cancer Discov. 2018 04; 8(4):417-427.
    View in: PubMed
    Score: 0.048
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.